
https://www.science.org/content/blog-post/stock-buybacks-roll
# The Stock Buybacks Roll On (September 2014)

## 1. SUMMARY
This article critiques the trend of pharmaceutical companies engaging in share buyback programs rather than investing in R&D or paying dividends. The author argues that buybacks are preferred by management—who often hold stock options—because they prop up share prices, whereas dividends are cash "out the door." The article suggests this reflects a timid, short-term managerial approach: spending on buybacks poses little career risk, whereas large R&D investments that fail can cost executives their jobs. It references previous posts on the topic and links to a Financial Times piece and Marginal Revolution discussion about whether buybacks are excessive, noting the tax-treatment explanation doesn't fully account for the continued rise in buybacks post-2003.

## 2. HISTORY
In the decade following this article, stock buybacks continued to be a major capital-allocation tool across industries, including biotech and pharmaceuticals. Public debate intensified as critics (including some policymakers) argued that massive buyback programs divert funds from R&D and long-term innovation. A few concrete developments shaped the landscape:

- **Corporate behavior**: Many large-cap pharma firms maintained substantial buyback programs, often alongside dividend increases. Companies like Pfizer, Merck, and Johnson & Johnson executed tens of billions in buybacks between the mid-2010s and early 2020s. The COVID-19 pandemic and supply-chain crises later drew criticism of stock distributions relative to capital investment and resilience.
- **Policy and regulation**: Some proposals emerged to constrain or penalize buybacks. For example, the U.S. Inflation Reduction Act of 2022 did not directly restrict buybacks but included measures aimed at reinvestment (drug pricing reforms, Medicare negotiation, and R&D incentives affecting biopharma capital allocation). In 2023, the U.S. enacted a 1% excise tax on corporate stock buybacks (beginning January 2023), intended to disincentivize them and encourage alternative uses of cash. Shorter-term efforts during the pandemic (CARES Act) briefly restricted buybacks for certain aid recipients, but those limits expired.
- **Investor and stakeholder pressure**: Institutional investors and pension funds increasingly scrutinized the R&D spending vs. shareholder return trade-offs. Some embraced ESG frameworks or stewardship codes that favor long-term value creation, while index investors generally accepted buybacks as a legitimate distribution mechanism.
- **Clinical pipelines and approvals**: Drug approvals proceeded on their own timelines (e.g., major approvals in oncology, immunology, and rare diseases), but the broader debate highlighted concerns that a short-term, buyback-heavy culture might reduce risk-taking in early-stage or platform R&D.

Overall, buybacks remained prevalent; concrete policy intervention remained modest and mixed, with the 1% excise tax representing the most direct U.S. action post-2014.

## 3. PREDICTIONS
- **Continued prevalence of buybacks**: The article implies buybacks would continue as a favored mechanism, driven by managerial incentives. This largely held true—data on U.S. corporate buybacks showed steady or elevated levels through the late 2010s and early 2020s, with pharma among the sectors conducting large recurring programs.
- **Risk-aversion explanation**: The author's hypothesis that "no one has ever been fired for doing it" suggests executives would keep choosing buybacks over high-risk R&D investments. While R&D spending did continue and even grow in many biopharma firms, the relative split of capital allocation often favored shareholder returns, confirming that buybacks remained a default safe choice for management teams.
- **(Implicit from linked discussions)**: The broader commentary threads the author cites likely included predictions about whether buybacks were "too high" and might crowd out dynamic investment. The subsequent empirical record is mixed—industry R&D investment persisted, but buyback critics continued to argue those funds could have supported more early-stage pipelines, platform technologies, or capital improvements if reinvested instead.

## 4. INTEREST
Rating: **6/10**
This article captures a durable tension in corporate governance and capital allocation within pharma and biotech. It remains relevant because the buyback debate evolved from academic discussion into modest policy intervention and broader scrutiny of public-company long-termism, though it is more commentary than investigative reporting.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20140923-stock-buybacks-roll.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_